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CORRESPONDENCE
Letters to the Editor
Fractional Flow Reserve–Guided
Intervention of Angiographically
Nonsignificant Coronary Stenoses
We read with interest the recent DEFER (Deferral Versus
Performance of PTCA in Patients Without Documented Ische-
mia) study by Pijls et al. (1) comparing results of percutaneous
coronary intervention (PCI) with medical therapy in patients with
stable coronary artery disease and angiographically intermediate
stenotic lesions. The study demonstrated no beneficial effects of
PCI in stenosis with fractional flow reserve (FFR) 0.75
(performance group) as compared with medical therapy (defer
group) and increased major adverse cardiac events (MACE) in
lesions with FFR 0.75 (reference group) during 5 years of
follow-up.
It is interesting to note the high frequency of coronary artery
bypass grafting (CABG) during 5 years of follow-up in the
reference group (10.4%), especially given the fact that two-thirds
of the patients had single-vessel disease, with normal left ventric-
ular ejection fraction (68  9), and few with diabetes (13%). This
figure is definitely high as compared with that seen in concurrent
studies such as COURAGE (Clinical Outcomes Utilizing Revas-
cularization and Aggressive Drug Evaluation) (2) and MASS II
(Second Medicine, Angioplasty, or Surgery Study) (3), with the
majority of their patients having multivessel coronary artery disease.
Seventy-seven patients (6.7%) in the PCI arm of the COURAGE
study underwent CABG after median 4.6 years, whereas MASS II
reported 9.3% during 5 years of follow-up.
The DEFER study defined myocardial infarction using a 2-fold
elevation of creatinine kinase, which is not a standard definition as
reported by the joint committee of European Society of Cardiol-
ogy/American College of Cardiology (4). Furthermore, the defi-
nition of acute myocardial infarction after PCI requires at least 3
times elevation above the upper limit of the normal (ULN) and
another study reported 5 to 8 times the ULN (5). We believe that
the definition used in the present study significantly increased the
events of myocardial infarction both in hospital and during
follow-up and might have led to increased MACE in the reference
group (FFR 0.75).
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Reply
We do not believe that the rate of coronary artery bypass grafting
in the reference group of the DEFER (Deferral Versus Perfor-
mance of PTCA in Patients Without Documented Ischemia)
study was high compared with that seen in other studies.
Although in the DEFER study the majority of patients had
single-vessel disease, the reference group only consisted of those
patients with proven ischemia (1). This is in contrast to the
COURAGE (Clinical Outcomes Utilizing Revascularization and
Aggressive Drug Evaluation) trial and many other trials. In those
trials (2), patients were classified according to angiographic crite-
ria, and it is well known that a significant number of angiographic
stenoses in those patients is not functionally important (i.e., not
responsible for reversible ischemia) and that from the functional
point of view, angiographic 2- or 3-vessel disease often becomes
1-vessel disease in terms of inducible ischemia (3,4).
In fact, one of the reasons why outcome after medical treatment
was reasonable compared with that seen with percutaneous coro-
nary intervention (PCI) in the COURAGE trial has been the fact
that in the PCI group, intervention was often performed on
relatively mild lesions, many of them most likely not functionally
significant. Performing PCI of such lesions (fractional flow reserve
[FFR] 0.75) creates a negative bias for PCI as demonstrated in
the perform group of the DEFER study. In contrast, also in the
COURAGE trial, PCI of ischemia-related stenosis (equivalent of
FFR 0.75 in a study) was significantly better than medical
treatment.
At the time when the DEFER study was performed (1997 and
1998), no consistent definition of myocardial infarction in enzy-
matic terms existed, and an increase to more than twice the normal
upper limit was often used. Nowadays, we would have taken a
3-fold increase as standardized in the recent guidelines of the
European Society of Cardiology (5). This would not have made
any fundamental difference for the outcome of the study.
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Drug-Eluting Stent
Implantation May
Not Affect Vasomotor
Function in Early Phase
The study by Obata et al. (1) demonstrates that drug-eluting stents
(DES) adversely affect endothelium-dependent vasomotor function
with a reduction in vascular endothelial growth factor (VEGF). This
report addressed a very important issue because it has been reported
that endothelialization and its function are impaired following
DES implantation (2,3). However, we are not convinced by the
findings in the present study that DES affect vasomotor function
2 weeks after implantation. As we have previously reported (4),
there is no histologic difference between DES and bare-metal
stents (BMS) within 2 weeks following implantation. Moreover,
vascular healing of the stented segment in acute myocardial
infarction generally takes a much longer time to complete than
stable plaques do in the case of both DES and BMS because these
lesions generally contain large necrotic cores. Therefore, it is
surprising that the authors report differences in response to
intracoronary acetylcholine because the extent and functionality of
endothelium for lesions stented with either DES or BMS lesions
is not different 2 weeks after implantation. Furthermore, angiog-
raphy cannot detect the underlying atherosclerotic disease in the
distal segments where vasomotor function was assessed, and it is
possible that the differences observed were due to differences in
atherosclerotic burden between the 2 groups because endothelial
function has been shown to be heavily influenced by the presence
of underlying atherosclerotic disease.
The authors also speculate that lack of VEGF in DES might be
responsible for impaired endothelialization or its function. As the
authors mentioned in the introduction, a compensatory up-regulation
of VEGF is usually observed when endothelium is denuded, whereas
VEGF is down-regulated upon complete re-endothelialization (5).
We do agree that high blood concentrations of sirolimus at an early
time point could impair endothelial cells in the portion distal to the
stent and be responsible for vasomotor dysfunction. However, the
sirolimus concentration in the anterior interventricular vein is far
below its IC50 (1.0 to 1.5 nmol/l) even at 3 days (0.5 nmol/l) and
even further below at 2 weeks (0.2 nmol/l) following implantation.
Even if sirolimus had a detrimental effect on endothelial cells in
the distal vessel, the VEGF level should be higher in the presence
of active ongoing arterial repair. In fact, our in vitro and in vivo
data clearly showed VEGF up-regulation after endothelial injury.
In our own assays, human umbilical vein endothelial cells are grown
until confluence and VEGF expression is measured using Cytokine
Array (RayBiotech Inc., Norcross, Georgia) in the presence and
absence of scratching or treatment with everolimus (2 nmol/l) for
16 h. The VEGF was greater in the scratched and everolimus group
(1.7  0.4- and 1.8  0.6-fold increase, respectively) as compared
with the nonscratched control group. Similarly, we have observed
up-regulation of VEGF messenger ribonucleic acid in the bare-metal
stented rabbit iliac arteries as compared with nonstented iliac arteries
at 7 days (1.4  0.2-fold-increase). Thus, VEGF is up-regulated in
the lesions where endothelialization is incomplete. It is hard to
reconcile these findings with those of Obata et al. (1). The vascular
biology of DES implantation is just being understood and larger
clinical studies as well as preclinical studies are needed to deepen
our understanding.
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